Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
BOSTON and ATLANTA, Jan. 16, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq:IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease, Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024. The Company’s Vice-President for Finance, Garth Lees-Rolfe, will be promoted to Chief Financial Officer.
Related news for (IKT)
- Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
- Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
- inhibikase therapeutics announces closing of up to $275 million financing and advancement of ikt-001pro into a late stage clinical trial in pulmonary arterial hypertension
- inhibikase therapeutics announces pricing of $110 million private placement to advance ikt-001pro, an optimized prodrug of imatinib, into a late-stage trial in pulmonary arterial hypertension
- 24/7 Market News Snapshot 09 October, 2024 – Inhibikase Therapeutics, Inc. Common Stock (NASDAQ:IKT)